Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
23 août 2021 08h00 HE
|
Heat Biologics
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces New Additions to Biothreat Advisory Board
19 août 2021 09h00 HE
|
Heat Biologics
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz DURHAM, N.C., Aug. 19,...
Heat Biologics Announces Formation of Biothreat Advisory Board
18 août 2021 08h00 HE
|
Heat Biologics
DURHAM, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Provides Second Quarter 2021 Business Update
11 août 2021 16h05 HE
|
Heat Biologics
DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics Announces Groundbreaking for New San Antonio Facility
09 août 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Joins Russell Microcap® Index
28 juin 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
23 juin 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
04 juin 2021 09h00 HE
|
Heat Biologics
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
20 mai 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
19 mai 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...